STOCK TITAN

Pulmatrix (PULM) Financials

PULM NASDAQ
Trailing 12 months to September 30, 2026
Revenue Not reported for the trailing 12 months
Net Income -$4.3M n/m YoY
EPS (Diluted) -$1.20 n/m YoY
Operating Cash Flow -$3.6M n/m YoY
Market Cap $4.9M as of Nov 16, 2026
Price / Sales n/m no full year of revenue reported yet
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 3.6x on $1.3M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 16, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 16, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PULM SEC filings page.

This page shows Pulmatrix, Inc. (PULM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PULM FY2025

Pulmatrix’s latest accounts show a sharply smaller operation still consuming cash, with spending now concentrated outside research.

The net loss of $5.162M nearly matches operating cash flow of -$5.433M, indicating little gap between reported losses and cash use. R&D spending fell from $7.166M in FY2024 to $38K, making the current cost base predominantly administrative rather than development-focused.

Assets fell from $9.943M in FY2024 to $4.139M in FY2025, while liabilities fell from $996K to $329K. That leaves liabilities at 7.9% of assets and the current ratio at 12.6x, describing a smaller but lightly encumbered balance sheet.

The reported liquidity comparison was 9 months of the latest annual operating outflow, a year-end balance-sheet comparison rather than a forecast. The combination of sharply reduced assets and continued negative operating cash flow shows that the company’s financial scale contracted faster than its cash-consuming operations ended.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for Pulmatrix, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Piotroski F-Score Partial
2/6

Pulmatrix, Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). No profitability signals pass, all 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing
N/A

Pulmatrix, Inc. reported a net loss of $5.2M while operations used $5.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income
-$1.2M
YoYn/m
QoQn/m
5Y CAGRn/m
10Y CAGRn/m

Pulmatrix, Inc. reported a net loss of $1.2M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.34
YoYn/m
QoQn/m

Pulmatrix, Inc. earned -$0.34 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Revenue

Not reported for Q3 2026.

EBITDA

Not reported for Q3 2026.

Cash & Balance Sheet

Cash & Debt
$1.4M
YoY-70.8%
QoQ-35.5%
5Y CAGR-51.8%
10Y CAGR-15.2%

Pulmatrix, Inc. held $1.4M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
4M
YoY0.0%
QoQ0.0%

Pulmatrix, Inc. had 4M shares outstanding in Q3 2026. That is unchanged from the same quarter a year earlier. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q3 2026.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity
-90.1%
YoY-71.6pp
QoQ-49.6pp
5Y change-72.0pp
10Y change-72.0pp

Pulmatrix, Inc.'s quarterly ROE was -90.1% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 71.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 49.6 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not reported for Q3 2026.

Net Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$1K
YoY-87.5%
QoQ-50.0%

Pulmatrix, Inc. invested $1K in research and development in Q3 2026. This represents a decrease of 87.5% from the same quarter a year earlier. Against the prior quarter it is down 50.0%.

Share Buybacks

Not reported for Q3 2026.

Capital Expenditures

Not reported for Q3 2026.

PULM Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PULM quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'25S-4/AQ3'2510-QQ2'2510-QQ1'2510-QQ4'24S-4/A
RevenueN/AN/AN/AN/AN/AN/AN/A$3K-99.9%
R&D Expenses$1K-87.5%$2K-85.7%$3K-84.2%N/A$8K-99.0%$14K-99.5%$19K-99.5%$6K-99.8%
SG&A Expenses$1.2M+42.2%$1.0M-31.9%$1.3M-29.5%$911K-53.3%$858K-61.2%$1.5M-23.3%$1.8M+12.4%$1.9M+113.9%
Operating Income-$1.2Mn/m-$1.0Mn/m-$1.3Mn/m-$908Kn/m-$866Kn/m-$1.5Mn/m-$1.8M-347.3%-$2.0Mn/m
EBITDAN/AN/AN/AN/AN/AN/AN/A-$2.0Mn/m
Income TaxN/AN/AN/A$0$0n/m$0n/m$0n/mN/A
Net Income-$1.2Mn/m-$1.0Mn/m-$1.2Mn/m-$928Kn/m-$877Kn/m-$1.5Mn/m-$1.8M-319.2%-$2.0Mn/m
EPS (Basic)-$0.34n/m-$0.29n/m-$0.32n/m-$0.25n/m-$0.24n/m-$0.42n/m-$0.50-317.4%-$0.55n/m
EPS (Diluted)-$0.34n/m-$0.29n/m-$0.32n/m-$0.25n/m-$0.24n/m-$0.42n/m-$0.50-317.4%-$0.55n/m
Diluted Shares (Avg)4M0.0%4M0.0%4M0.0%N/A4M0.0%4M0.0%4M0.0%N/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.

PULM Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PULM quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'25S-4/AQ3'2510-QQ2'2510-QQ1'2510-QQ4'24S-4/A
Total Assets$2.4M-52.6%$3.2M-47.2%$4.5M-44.2%$4.1M-58.4%$5.0M-56.7%$6.2M-61.0%$8.1M-73.5%$9.9M-70.7%
Current Assets$2.4M-52.6%$3.2M-47.3%$4.5M-44.2%$4.1M-58.4%$5.0M-56.6%$6.1M-60.7%$8.0M-54.3%$9.9M-52.4%
Cash & Equivalents$1.4M-70.8%$2.2M-62.8%$3.3M-56.9%$4.1M-57.1%$4.8M-55.5%$5.8M-52.9%$7.7M-52.7%$9.5M-50.3%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Accounts ReceivableN/AN/AN/AN/AN/AN/A$16K-97.2%N/A
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$1.0M+308.4%$689K+25.7%$905K+0.1%$329K-67.0%$249K-57.8%$548K-77.8%$904K-92.1%$996K-93.8%
Current Liabilities$1.0M+308.4%$689K+25.7%$905K+0.2%$329K-64.6%$249K-57.8%$548K-77.8%$903K-71.3%$929K-76.2%
Non-Current Liabilities$0n/m$0n/m$0-100.0%$0-100.0%$0n/m$0n/m$1K-100.0%$67K-99.4%
Total Equity$1.3M-71.6%$2.6M-54.4%$3.6M-49.8%$3.8M-57.4%$4.7M-56.7%$5.6M-57.9%$7.1M-62.4%$8.9M-50.3%
Retained Earnings-$305.7Mn/m-$304.5Mn/m-$303.5Mn/m-$302.3Mn/m-$301.4Mn/m-$300.5Mn/m-$299.0Mn/m-$297.2Mn/m

Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.

PULM Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PULM quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'25S-4/AQ3'2510-QQ2'2510-QQ1'2510-QQ4'24S-4/A
Operating Cash Flow-$770Kn/m-$1.1Mn/m-$1.1Mn/m-$706Kn/m-$1.0Mn/m-$1.9Mn/m-$1.8Mn/m-$1.3Mn/m
Depreciation & AmortizationN/AN/AN/AN/AN/AN/AN/A$0-100.0%
Stock-Based Compensation$2K-66.7%$2K-66.7%$3K-62.5%N/A$6K-97.0%$6K-94.2%$8K-96.0%N/A
Capital ExpendituresN/AN/AN/AN/AN/AN/AN/A$0-100.0%
Free Cash FlowN/AN/AN/AN/AN/AN/AN/A-$1.3Mn/m
Investing Cash FlowN/AN/AN/AN/AN/AN/AN/A$0n/m
Financing Cash Flow$0-$50K$1.0MN/AN/AN/AN/AN/A

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

PULM Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PULM quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'25S-4/AQ3'2510-QQ2'2510-QQ1'2510-QQ4'24S-4/A
Operating MarginN/AN/AN/AN/AN/AN/AN/A-65066.7%
Net MarginN/AN/AN/AN/AN/AN/AN/A-66200.0%
Return on Equity-90.1%-71.6pp-40.5%-12.9pp-32.6%-7.3pp-24.4%-2.2pp-18.5%+5.2pp-27.6%+16.0pp-25.3%-29.6pp-22.2%-10.6pp
Return on Assets-51.3%-33.7pp-31.9%-6.7pp-26.1%-3.6pp-22.4%-2.5pp-17.6%+4.9pp-25.2%+11.6pp-22.5%-25.2pp-20.0%-13.8pp
Current Ratio2.32-17.7x4.70-6.5x4.96-3.9x12.55+1.9x19.97+0.6x11.21+4.9x8.90+3.3x10.68+5.3x
Liabilities-to-Equity0.76+0.7x0.27+0.2x0.25+0.1x0.090.0x0.050.0x0.10-0.1x0.13-0.5x0.11-0.8x
Asset TurnoverN/AN/AN/AN/AN/AN/AN/A0.00-0.1x
FCF MarginN/AN/AN/AN/AN/AN/AN/A-42033.3%

Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Pulmatrix, Inc. PULM FY2025 N/A -$5.2M N/A $4.9M —
Kiora Pharmaceuticals, Inc. KPRX FY2025 $0 -$10.8M N/A $4.3M —
Processa Pharmaceuticals, Inc. PCSA FY2025 N/A -$13.6M N/A $4.8M —
Skye Bioscience, Inc. SKYE FY2025 N/A -$55.9M N/A $4.7M —
Can-Fite BioPharma Ltd. CANF FY2025 $405K -$9.8M N/A $4.7M —
Silo Pharma, Inc. SILO FY2025 $72K -$4.2M N/A $3.7M —

Frequently Asked Questions

No, Pulmatrix, Inc. (PULM) reported a net loss of $4.3M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $5.2M.

Pulmatrix, Inc. (PULM) reported diluted earnings per share of -$1.41 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Pulmatrix, Inc. (PULM) has a return on equity of -135.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Pulmatrix, Inc. (PULM) recorded an outflow of $5.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Pulmatrix, Inc. (PULM) had $4.1M in total assets as of fiscal year 2025, including both current and long-term assets.

Pulmatrix, Inc. (PULM) invested $38K in research and development during fiscal year 2025.

Pulmatrix, Inc. (PULM) had 4M shares outstanding as of fiscal year 2025.

Pulmatrix, Inc. (PULM) had a current ratio of 12.55 as of fiscal year 2025, which is generally considered healthy.

Pulmatrix, Inc. (PULM) had a liabilities-to-equity ratio of 0.09 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Pulmatrix, Inc. (PULM) had a return on assets of -124.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Pulmatrix, Inc. (PULM) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $4.9M as of Nov 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Pulmatrix, Inc. (PULM) has no price-to-sales ratio at the moment: no full year of revenue reported yet. The market capitalization is $4.9M as of Nov 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Pulmatrix, Inc. (PULM) held $4.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $5.4M over that year. Dividing the one by the other, the reported balance equals about 9 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Pulmatrix, Inc. (PULM) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Pulmatrix, Inc. (PULM) reported a net loss of $5.2M while operations used $5.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Back to top